Indian hospital stocks have been in the news for the past few weeks. The reason is a case in the Supreme Court about how much patients pay for medicines, especially cancer drugs. The Centre has now told the court that trade margins on some cancer drugs average around 170% and can go as high as 700%.
This raises a simple question for investors. If the court and the government start limiting what hospitals can earn on medicines, what happens to the profits of listed hospital chains? This article explains the case in simple words, what the government has said, and how the market has reacted so far.
What Is the Case About?
The case was filed by Kishan Chand Jain. It asks for generic medicine prescriptions, price control on more medicines, and price caps on medical devices. Here is how it unfolded in the Supreme Court:
- September 22: The court was told that a cancer drug sold to retailers for ₹2,700 had a printed price (MRP) of ₹27,000. The court called this “broad daylight dacoity”, which means robbery in open daylight.
- September 29: The court called the 10 times markup “carnage” and asked whether a uniform 16% margin should apply to all medicines.
- The court also asked the Centre to look into complaints that hospitals push patients to buy medicines only from their own pharmacies.
What Does the Government Say in Its Affidavit?
An affidavit is a written statement that is submitted to the court. The Centre filed a detailed 551-page affidavit. These are the main points:
- Trade margins on non-scheduled cancer drugs average around 170% and can reach 700%.
- The government has decided to cap the trade margin on cancer drugs at 30% of the MRP.
- This is expected to bring down the MRP of cancer drugs by 20% to 70%.
- Patients are expected to save around ₹2,500 crore every year.
- The cap covers branded and generic drugs, imported and Indian-made drugs, and patented drugs.
- At first, it applies to all cancer drugs except low-cost ones.
The Centre also told the court that one common cap for all medicines may not work. Separately, the government is checking the gap between the buying price and the MRP of items that hospitals use, such as consumables.
Scheduled and Non-Scheduled Drugs in Simple Words
To understand why this gap exists, you need to know the difference between two types of medicines.
- Scheduled drugs: These are around 1,000 medicines on the government’s essential list. The government fixes a maximum price for them.
- Non-scheduled drugs: These are all the other medicines, which make up about 82% of the market. Companies set their own launch price and can raise it by up to 10% every year.
- Trade margin: This is the extra amount added between the price a retailer pays and the MRP printed on the pack.
Because non-scheduled drugs have no upfront price limit, a few of them end up with very high MRPs. The ₹2,700 to ₹27,000 example is an extreme case. The 170% average and the 700% maximum show the wider pattern for non-scheduled cancer drugs.
This is not the first such step. In 2019, the National Pharmaceutical Pricing Authority capped the trade margin at 30% for 42 non-scheduled cancer drugs.
Why Did Hospital Stocks Fall?
Hospitals earn a good part of their income from pharmacies and medical supplies. Drugs and consumables make up around 25% to 30% of the bill in large hospitals. So when the court questioned medicine margins, investors worried about future profits.
- September 30: Hospital companies lost about ₹24,800 crore in market value in one day. The BSE Hospitals index fell 5%.
- Apollo Hospitals fell 5.7%, Fortis Healthcare fell 6.3% and Max Healthcare fell 5.3%.
- October 1: Hospital stocks fell again for a second day. Jefferies noted that the sector had corrected by around 15% to 20%.
Early on, one analyst said the fall was mostly about sentiment, because the court had only made remarks and no final rule had been made.
How Did the Market React to the 30% Cap?
The reaction was mixed, and it changed from day to day.
- October 9: Apollo, Max and Fortis rose between 2% and 5%. Investors felt that a 30% cap was easier to handle than the 16% margin that the court had mentioned.
- On the same day, Healthcare Global Enterprises (HCG) fell nearly 6%. It is a cancer-focused hospital chain, so the cap matters more for its business.
- October 12: Hospital stocks fell again, by up to 3%, after the court said the Centre’s response on cancer drugs was not enough. The court asked why other medicines were left out. Park Medi World fell as much as 6%.
- October 14: The Nifty Pharma index fell 1.3% and the Nifty Healthcare index fell 1.25% as uncertainty over medicine pricing continued.
What Are Analysts Saying?
Most analysts feel the long-term story for hospitals is still strong, but they accept that the short-term risk is real.
- Cancer drugs account for around 4% to 6% of hospital revenue.
- Jefferies estimated a hit of about 2% to 5% to hospital operating profit, if cancer drug margins are capped at 16% and margins on consumables are limited to 5%.
- Jefferies also believes that the ₹27,000 example is an exception and not the normal practice.
- A 30% cap does not mean every drug price will fall by 30%. The actual impact will depend on the drug and its current margin.
Key Things to Watch Next
- The next hearing: The Supreme Court will hear the matter again on October 27.
- Other medicines: The court has asked why the cap is limited to cancer drugs. A wider cap would affect more of a hospital’s pharmacy income.
- In-house pharmacies: Any rule that stops hospitals from pushing patients to their own pharmacies could change pharmacy sales.
- Quarterly results: Hospital companies may explain how much pharmacy and cancer drugs add to their profits when they announce their results.
- Type of hospital: Chains that depend more on cancer care may feel a bigger impact than multi-speciality chains.
What This Means for Investors
Court cases and new rules can move a sector quickly, even before any final decision. That is why it helps to look at the facts and not only the headlines. If you want to understand how sector stories like this fit into a long-term plan, you can read our explainer on healthcare sector investing in India.
Here are a few simple points to keep in mind:
- Check how much of a hospital’s income comes from pharmacy and cancer drugs.
- Follow the court dates and government announcements, since they can change the story quickly.
- Remember that a share price fall on a news day does not always match the real impact on profits.
- Avoid making decisions based on one day’s price move.
For more updates on how court rulings and government rules affect the market, you can follow our stock market news and analysis.
Conclusion
For hospital companies, the effect on profits looks limited for now. Cancer drugs are only a small part of their revenue, and analysts still see a strong long-term future for the sector. But the matter is not settled yet. The court wants to know why other medicines are left out, and a wider cap could affect hospital pharmacy income.
One cancer drug has put every big hospital chain’s profits under watch. The court has asked why the cap should stop at cancer drugs. The next hearing is on 27 October, and it will tell how far this can go.
Disclaimer: TejiFactor is a SEBI-regulated platform. This article is for educational and informational purposes only and should not be treated as investment advice. Investments in the securities market are subject to market risks. Please read all related documents carefully and consult a SEBI-registered investment advisor before making any investment decision.